Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT01316120
Other study ID # HPVDry
Secondary ID
Status Enrolling by invitation
Phase N/A
First received March 15, 2011
Last updated December 22, 2011
Start date November 2010
Est. completion date December 2011

Study information

Verified date December 2011
Source University Hospital, Geneva
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

Human papillomavirus (HPV) assays are likely to be used in cervical cancer screening. Our objective is to simplify the method of collection of female genital tract specimens by determining if vaginal dry swabs are as accurate as the standard transport medium for HPV diagnosis.


Description:

High-risk human papillomavirus (HR-HPV) infections in women are clinically important because they have been associated with nearly all cases of preinvasive and invasive cervical neoplasia1. Genital HR-HPV related infection is common, affecting approximately 10-25% of women, depending on the population and age-groups studied2-4.

With the advance in our understanding of HPV biology and the development of technologies for HPV detection together with the poor sensitivity of a single Pap test, there has been now a growing interest concerning the potential use of HPV DNA testing as a screening tool for cervical cancer5.

Currently, there is no consensus on which sampling method is the most effective for HPV DNA testing. These last years, studies have reported that samples provided by women themselves were suitable for DNA testing and support the feasibility of self-collection for HPV DNA testing6-8. Data from these studies support that it is acceptable for the women and demonstrated that a fairly high concordance rate between the self- and physicians testing method has been achieved.

Potential advantage of self-collection is that it could improve access to health care, reduce healthcare costs and save time for patients and providers. Available data have been reported with the use of specimen transport medium (STM), but the use of dry vaginal swab may potentially offer similar reliability than standard STM. Small studies suggest that HPV test (PCR) sampled by physicians using dry vaginal swab seems to be as accurate as those performed in a standard medium for HPV detection9,10. Dry vaginal swab offers potential advantages in terms of being more convenient for collection and is less expensive than a vaginal swab placed in a transport medium.

The aim of our study is to assess the performance of self-obtained v-DRY versus "standard" v-STM and its acceptability.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 120
Est. completion date December 2011
Est. primary completion date August 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years and older
Eligibility Inclusion Criteria:

- 20 years or older,

- First consultation in our colposcopy unit,

- Understands study procedures and accepts voluntarily to participate by signing the informed consent form (ICF).

Exclusion Criteria:

- Previous hysterectomy,

- Pregnant,

- Virgin,

- Not able to comply with the protocol study.

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Other:
Compare different self-obtained specimen for HPV identification
Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
Compare different self-obtained specimen for HPV identification
Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Geneva

Outcome

Type Measure Description Time frame Safety issue
Primary To assess sensibility and specificity of dry swabs for HPV diagnosis Agreement between collection methods in terms of HPV risk categories will be measured using the kappa statistic ( ) with a precision of 10% (95% confidence interval). This measure of agreement is 0 when the amount of agreement is what would be expected by chance and 1 when there is perfect agreement. day 1 No
Secondary Preference about HPV self-collection Women will complete a self administered questionnaire on demographics and preference for sampling method (Dry versus standard) day 1 No
Secondary Sensitivity and specificity of specimen transport medium (STM) Sensitivity and specificity to detect high-risk HPV using v-STM as gold standard will be reported. day 1 No
See also
  Status Clinical Trial Phase
Completed NCT05458869 - Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
Completed NCT01932697 - Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer Phase 2
Completed NCT03265743 - HPV Vaccination in Women With Cystic Fibrosis N/A
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A
Completed NCT06199128 - Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients
Active, not recruiting NCT01824537 - Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Phase 4
Completed NCT01265212 - Prevalence of Human Papillomavirus in Men Living in the Northern Plains N/A
Terminated NCT01082861 - Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination Phase 4
Unknown status NCT01087164 - Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers N/A
Completed NCT00572832 - Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting N/A
Completed NCT03158220 - Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Phase 3
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Completed NCT05680454 - A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine Phase 1
Completed NCT04133610 - HPVPro Study: Comparison of HPV Detection in Clinician-collected Cervical Swabs and Self-sampled Cervicovaginal Swabs N/A
Completed NCT00988884 - A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005) Phase 3
Not yet recruiting NCT05981807 - HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
Recruiting NCT03302858 - A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Phase 2
Completed NCT01694875 - Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System N/A
Completed NCT01205412 - An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain N/A